Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Jiangsu Hansoh Pharmaceutical Group Co Ltd (Hansoh Pharma), a subsidiary of Hansoh Pharmaceutical Group Co Ltd, is a pharmaceutical company that research, develops, manufactures, and markets drugs. The company's products include aumolertinib mesylate tablets, flumatinib mesylate tablets, pegmolesatide injection, PEG-loxenatide injection, inebilizumab injection, tenofovir amibufenamide tablets, and morinidazole sodium chloride injection, among others. It offers its products in various therapeutic areas, including oncology, anti-infectives, central nervous system disorders, metabolic diseases, and autoimmune diseases. The company markets its products under Ameile, Hansoh Xinfu, Saint Luolai, Fulaimei, Xinyue, Hengmu and Mailingda, among others. Hansoh Pharma is headquartered in Lianyungang, Jiangsu, China.
Headquarters
China
Address
Huaguoshan Avenue, No. 9, Dongjin Road, Lianyungang, Jiangsu
Website
www.hansoh.cn/en/
Telephone
86 518 83096666
Industry
Pharmaceuticals and Healthcare
Jiangsu Hansoh Pharmaceutical Group Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Bortezomib for Injection | Quality Management Services | Xinmei |
| Aumolertinib Mesylate Tablets | Marketing Services | Ameile |
| Flumatinib Mesylate Tablets | Lean Manufacturing Services | Hansoh Xinfu |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In March, the company received approval from the National Medical Products Administration for the marketing of XINYUE (Inebilizumab Injection) for the treatment of adult patients with generalized myasthenia gravis positive for anti-acetylcholine receptor or anti-muscle-specific kinase antibodies. |
| 2026 | Regulatory Approval | In February, the company received approval from the European Union for Aumolertinib Mesylate Tablets as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer. |
| 2025 | Contracts/Agreements | In October, the company signed a license agreement with Roche for HS-20110, a CDH17-targeting antibody-drug conjugate. |
Competitor Comparison
| Key Parameters | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Frontier Biotechnologies Inc | Beijing Tide Pharmaceutical Co Ltd | China Biologic Products Holdings Inc | Yangtze River Pharmaceutical Group |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Lianyungang | Nanjing | Beijing | Beijing | Taizhou |
| State/Province | Jiangsu | Jiangsu | Beijing | Beijing | Jiangsu |
| No. of Employees | - | 302 | - | - | 20,000 |
| Entity Type | Private | Public | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Zhong Huijuan | Chief Executive Officer; Director | Executive Board | - | - |
| Sun Yuan | Director; Director - Executive | Executive Board | - | - |
| Lyu Aifeng | Director - Executive; Director | Executive Board | - | - |
| Hu Min | Chief Financial Officer | Senior Management | - | - |
| Jiang Shan | Chief Technology Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer